前列腺特异性抗原密度、前列腺健康指数及前列腺健康指数密度预测前列腺穿刺阳性结果的效用取决于前列腺穿刺方法
该回顾性队列纳入211例至少1个可疑MRI病灶且PI-RADS≥3并接受穿刺的患者(2015-2017年),比较融合与非融合穿刺下PSA、PHI、PSAD、PHID对前列腺癌穿刺阳性的预测价值。PHI在非融合穿刺中AUC为0.78,PHID在融合穿刺中AUC为0.82,均优于PSA或PSAD;基于Youden指数,非融合穿刺PHI cutoff 45.9可减少77.3%阴性穿刺但漏诊19%临床显著癌,融合穿刺PHID cutoff 0.64可减少63.4%阴性穿刺但漏诊12%临床显著癌。结论认为预测标志物的选择取决于穿刺引导方法,体积指数衍生指标在MRI-US融合穿刺中似乎更有价值。
要点
- PHI在非融合穿刺中预测阳性AUC为0.78,PHID在融合穿刺中AUC为0.82,均优于PSA或PSAD。
- 非融合穿刺PHI cutoff 45.9可减少77.3%阴性穿刺,但漏诊19%临床显著癌。
- 融合穿刺PHID cutoff 0.64可减少63.4%阴性穿刺,但漏诊12%临床显著癌。
核心结论
- 预测前列腺穿刺阳性的标志物选择取决于穿刺引导方法,体积指数衍生指标在MRI-US融合穿刺中似乎更有价值。
研究设计与样本
- 回顾性队列纳入211例至少1个可疑MRI病灶、PI-RADS≥3并接受穿刺的患者(2015-2017年)。
- 121例接受非融合穿刺,90例接受融合穿刺。
主要发现
- PHI在非融合穿刺中预测阳性AUC为0.78(95% CI 0.67-0.88),PHID在融合穿刺中AUC为0.82(95% CI 0.73-0.91),均优于PSA或PSAD。
- 多变量模型与单变量相比未改善模型拟合。
- 基于Youden指数,非融合穿刺PHI cutoff 45.9可减少77.3%阴性穿刺,但漏诊19%临床显著癌。
- 基于Youden指数,融合穿刺PHID cutoff 0.64可减少63.4%阴性穿刺,但漏诊12%临床显著癌。
关键数值与推荐
- 非融合穿刺中PHI的AUC为0.78(95% CI 0.67-0.88)。
- 融合穿刺中PHID的AUC为0.82(95% CI 0.73-0.91)。
- 非融合穿刺PHI cutoff 45.9减少77.3%阴性穿刺,漏诊19%临床显著癌。
- 融合穿刺PHID cutoff 0.64减少63.4%阴性穿刺,漏诊12%临床显著癌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate prognostic markers, prostate-specific antigen, prostate health index (PHI), and prostate volume indexed measures (prostate-specific antigen density and prostate health index density) for predicting positive prostate cancer biopsies in magnetic resonance (MR) transrectal ultrasound fused versus nonfused transrectal ultrasonography biopsy. METHODS: A retrospective cohort of 211 patients that had at least 1 suspected MR lesion, Prostate Imaging-Reporting and Data System ≥3, and subsequent biopsy (2015-2017). Clinical characteristics and prognostic biomarkers were evaluated as predictors of prostate cancer detection by type of biopsy guidance (fused vs nonfused). RESULTS: One-hundred twenty-one patients had nonfused and 90 had fused biopsies. PHI and PHID had greater area under the receiver operating characteristics curve (AUC) in predicting positive biopsies than prostate-specific antigen or PSAD for both nonfused and fused biopsy. PHI 0.78 (95% CI 0.67-0.88) and PHID 0.82 (95% CI 0.73-0.91) had the greatest AUC for predicting biopsy results for nonfused and fused biopsies, respectively. Multiple-variable models did not improve model fit compared to single variables. Based on Youden's index, a cut-off value of 45.9 for PHI in nonfused and 0.64 for PHID in fused biopsies would reduce the number of negative biopsies by 77.3% and 63.4%, respectively, but the percentage of missed clinically significant cancer biopsies would be 19% and 12%, respectively. CONCLUSION: Our findings demonstrate that the choice of prognostic biomarkers for predicting positive biopsies is a function of the biopsy guidance method. Volume indexed derivatives appear to have greater value when a MRI-US fused method is used.
引用
- Lopes Vendrami C, McCarthy RJ, Chatterjee A, et al. The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods. Urology. 2019. PMID: 30926382. doi:10.1016/j.urology.2019.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。